Xaluritamig
Xaluritamig is Amgen's T-cell engager for prostate cancer, now in two phase 3 trials, aiming to do for prostate cancer what tarlatamab did for small-cell lung cancer.
Phase 1 (ESMO 2024): PSA50 ~49% and confirmed responses in heavily pretreated mCRPC at high doses; CRS mostly grade 1-2 with step-up dosing. XALute (NCT06691984, n≈675, post-taxane, vs cabazitaxel or ARPI, OS primary; active, not recruiting as of mid-2026) and XALience (with abiraterone, chemo-naive mCRPC).
Compare all products across the US, EU, UK, Japan, China and Australia →
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials in OnCo
Latest papers
topQuery for this drug: (TITLE:"Xaluritamig" OR ABSTRACT:"Xaluritamig" OR TITLE:"AMG 509" OR ABSTRACT:"AMG 509") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Xaluritamig, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductPasritamig
Shares CD3, Cytokine release syndrome (CRS), T-cell engagers (bispecific), Prostate cancer.
- TermPSA (prostate-specific antigen)
Shares PSA50 / PSA90 response, Prostate cancer.
- ProductCabazitaxel
Shares XALute, Prostate cancer.
- PersonOwen N. Witte
Shares STEAP1, Prostate cancer.
- TrialTheraP (ANZUP 1603)
Shares PSA50 / PSA90 response, Prostate cancer.
- CompanyXencor
Shares CD3, T-cell engagers (bispecific).
- ProductElranatamab
Shares CD3, Cytokine release syndrome (CRS), T-cell engagers (bispecific).
- TrialTOWER
Shares CD3, T-cell engagers (bispecific).